DGLA to their respective metabolites, the relative contributions of these oxylipin products to the inhibitory effects of DGLA on platelet function remain unclear. Furthermore, the antiplatelet effects of DGLA have been primarily attributed to the COX-1-derived metabolites that have been shown to inhibit platelet activation. [4] [5] [6] 11 However, the DGLA-derived products of COX-1 (TXA 1 and prostaglandin E1) are liable and produced in low amounts in platelets. [12] [13] [14] [15] In addition, a recent study demonstrated that 12(S)-hydroxy-8Z,10E,14Z-eicosatrienoic acid (12(S)-HETrE), the 12-LOX-derived oxylipin of DGLA, exhibits a potential antiplatelet effect ex vivo. 16 Hence, it is important to delineate whether 12-LOX is required for DGLA-mediated inhibition of platelet function in vivo and whether DGLA and 12(S)-HETrE play an essential role in regulation of thrombosis.
This study showed that an ω-6 PUFA, DGLA, inhibited platelet thrombus formation in vivo after an insult to the vessel wall. Interestingly, DGLA was unable to inhibit thrombus formation in 12-LOX −/− mice, suggesting that the antithrombotic effects of DGLA were mediated by 12-LOX. The 12-LOX-derived oxylipin of DGLA, 12(S)-HETrE, potently impaired thrombus formation after vessel injury irrespective of 12-LOX expression. Importantly, the antithrombotic effects of 12(S)-HETrE did not disrupt primary hemostasis or result in increased bleeding. Finally, the antiplatelet effect of 12(S)-HETrE was delineated here and shown to inhibit platelet function through the activation of the Gs α subunit (Gα s ) signaling pathway leading to the formation of cAMP and protein kinase A (PKA) activation in the platelet. Hence, these findings demonstrate an antithrombotic role of DGLA 12(S)-HETrE at both the mechanistic and in vivo levels.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

DGLA Inhibits Platelet Aggregation and Thrombus Growth in a 12-LOX-Dependent Manner
Treatment of human platelets with either DGLA [4] [5] [6] or its 12-LOX-derived metabolite, 12(S)-HETrE, potently inhibited platelet aggregation 16 ; however, the relative contribution of 12-LOX to DGLA-mediated inhibition of platelet activation was unclear. To assess the role of 12-LOX in DGLA-mediated platelet inhibition, washed platelets from WT or 12-LOX −/− mice were stimulated with an EC 80 concentration of either protease-activated receptor-4-activating peptide (PAR4-AP) or collagen in the presence or absence of DGLA. As previously reported, platelets from 12-LOX −/− mice were hypoactive compared with platelets from WT mice, 17 hence, requiring a higher concentration of agonist to reach EC 80 . Pretreatment of platelets from WT mice with DGLA resulted in significant inhibition of aggregation compared with DMSO-treated platelets in response to PAR4-AP or collagen stimulation ( Figure 1A and 1B). Conversely, DGLA treatment of platelets from 12-LOX −/− mice failed to inhibit platelet aggregation in response to PAR4-AP or collagen stimulation ( Figure 1A and 1B). To fairly compare the concentrations of the higher PAR4-AP concentration used on 12-LOX −/− platelets, WT platelets treated with DGLA were also stimulated with higher PAR4-AP concentration, resulting in significant inhibition of platelet aggregation compared to vehicle control (data not shown). As the observed DGLA-mediated inhibition of aggregation may be because of the modification of the lipid membrane structure thus affecting platelet signaling or activation, other PUFAs including linoleic acid and arachidonic acid (AA) were used as controls to rule out a lipid membrane insulating effect in platelet activation. 18 Pretreatment of platelets with either linoleic acid or AA had no inhibitory effect on PAR4-AP or collagen-mediated platelet aggregation compared with vehicle alone ( Figure 1A and 1B).
To determine whether DGLA inhibited platelet aggregation by impinging on intracellular signaling, the activation of Rap1, a common signaling effector required for integrin α IIb β 3 activation was assessed in DGLA-treated platelets stimulated with PAR4-AP. [19] [20] [21] In platelets isolated from WT mice, DGLA inhibited Rap1 activation at all concentrations of PAR4-AP tested ( Figure 1C ). Because DGLA was unable to inhibit platelet aggregation in 12-LOX −/− mice, we assessed whether 12-LOX was also necessary for DGLA inhibition of Rap1 activation in platelets. Consistent with the platelet aggregation data, DGLA was unable to inhibit Rap1 activation in platelets from 12-LOX −/− mice at any of the concentrations of PAR4-AP tested ( Figure 1C ). Together, these data demonstrate that the antiplatelet effects mediated by DGLA require 12-LOX.
To determine whether the antiplatelet effects of DGLA observed ex vivo could contribute to the inhibition of platelet thrombus formation in vivo, a laser-induced cremaster arteriole thrombosis model was used to examine thrombus formation (platelet and fibrin) in WT mice 22 (Figure 1D through 1F). Mice were intravenously injected with either vehicle control (DMSO) or 50 mg/kg of DGLA 10 minutes before the initiation of thrombosis by laser injury. After vessel injury of vehicle control-treated WT mice, fluorescently labeled platelets rapidly accumulated at the site of vascular injury then drastically diminished in size as the clot was resolved ( Figure 1D and 1E; Movie I in the online-only Data Supplement). Simultaneously, fibrin formation can be seen at the base of the developing thrombus of vehicle control-treated WT mice ( Figure 1D treated with DGLA showed a significant reduction in platelet, but not in fibrin accumulation ( Figure 1D and 1E; Movie II in the online-only Data Supplement). Figure 1A through 1C suggests a requirement for 12-LOX in DGLA-mediated inhibition of platelet activation ex vivo.
To determine whether this observation translates to an attenuation of platelet reactivity in vivo, thrombus formation was measured in 12-LOX −/− mice after laser-induced injury of the cremaster arteriole ( Figure 1D and 1F). As previously reported, platelets from 12-LOX −/− mice exhibited a bleeding diathesis compared with WT mice as determined by the tail-bleeding assay. 17 Therefore, it would be expected that the 12-LOX −/− mice show a significant attenuation of thrombus after injury compared with the WT (Figure 1D and 1F). Interestingly, the accumulation of platelet and fibrin in thrombi between DGLA-treated 12-LOX −/− and vehicle control did not differ ( Figure 1D and 1F; Movies III and IV in the online-only Data Supplement) supporting the ex vivo observation that 12-LOX is required to mediate DGLA-dependent inhibition of platelet function and thrombosis.
12-LOX Oxylipin, 12(S)-HETrE, Inhibits Platelet Aggregation and Thrombus Growth
To confirm that 12(S)-HETrE was the 12-LOX product of DGLA mediating the inhibitory effects observed in Figure  1 , washed platelets from either WT or 12-LOX −/− mice were treated with 12(S)-HETrE followed by stimulation with either PAR4-AP or collagen. Notably, 12(S)-HETrE (25 μmol/L) inhibited the aggregation of platelets from WT and 12-LOX −/− mice similar in response to PAR4-AP or collagen ( Figure  1B and 2A). As expected, no decrease in collagen-or PAR4-AP-mediated platelet aggregation was observed in either WT or 12-LOX −/− platelets pretreated with 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12-HETE), the prothrombotic 12-LOX-derived oxylipin of AA, compared with vehicle control. In addition, incubation of platelets with 12(S)-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid, a 12-LOX-derived oxylipin of eicosapentaenoic acid with no known effects on aggregation, 16,23,24 did not inhibit collagenor PAR4-AP-induced aggregation in platelets from either WT or 12-LOX −/− mice.
To determine whether 12(S)-HETrE inhibited intracellular signaling, the activation of Rap1 was measured in PAR4-AP-stimulated platelets in the presence of 12(S)-HETrE or vehicle control. 12(S)-HETrE suppressed Rap1 activation compared with vehicle control in platelets from either WT or 12-LOX −/− mice ( Figure 2C ). Thus, 12(S)-HETrE was able to inhibit platelet aggregation and Rap1 activity independent of 12-LOX expression.
Although 12(S)-HETrE significantly attenuated platelet activation, it remained unclear whether 12(S)-HETrE could directly inhibit platelet thrombus formation in vivo. To evaluate the effects of 12(S)-HETrE on thrombus formation, the size and kinetics of the growing arterial thrombus were assessed after laser-induced injury of the cremaster muscle arterioles in WT and 12-LOX −/− mice treated with vehicle control or 6 mg/ kg of 12(S)-HETrE ( Figure 1D and 2D). After injury, platelets and fibrin were observed to rapidly accumulate at the injured arteriole wall in WT control mice ( Figure 2D ; Movie I in the online-only Data Supplement). In contrast, WT mice treated with 12(S)-HETrE had significantly smaller and less stable thrombi in response to laser injury as assessed by both platelet and fibrin accumulation ( Figure 2D 
DGLA-Induced Oxylipin Production
Endogenously, only minute amounts of DGLA metabolites are produced by COX-1 (prostaglandin E1 and thromboxane B1) or 12-LOX (12(S)-HETrE) because of the low abundance of DGLA in the platelet plasma membrane. 25 To determine whether the exogenous addition of DGLA (10 μmol/L) increases the production of 12-LOX and COX-1 metabolites, the lipid releasate from platelets stimulated with PAR4-AP in the presence of vehicle control or DGLA was measured by liquid chromatography/tandem mass spectrometry (LC/MS/ MS). As expected, the amount of DGLA-dependent COX-1 and 12-LOX oxylipins was significantly potentiated in the DGLA-treated group compared with the DMSO control group ( Figure 3A and 3B ). The amount of AA-dependent metabolites from either 12-LOX (12-HETE) or COX-1 (thromboxane B2 or prostaglandin E2) was unaltered in platelets incubated with DGLA ( Figure 3A and 3B), supporting 12-LOX being in excess such that competition for the substrate is not necessary. This is a reasonable presumption based on previously published work showing that in the human platelet transcriptome, the mRNA for 12-LOX, ALOX12, is expressed in the top 8% of all transcripts in the platelet. 26 
12(S)-HETrE Does Not Disrupt Hemostasis
Because 12(S)-HETrE potently attenuated platelet accumulation in the laser-induced cremaster arteriole injury model of thrombosis, it is possible that 12(S)-HETrE also alters hemostasis resulting in increased bleeding. To determine whether 12(S)-HETrE treatment resulted in an increased bleeding diathesis, 2 hemostatic models were used to assess the impact of 12(S)-HETrE on bleeding. Initially, the tailbleeding time assay was utilized to determine the effects of 12(S)-HETrE on primary hemostasis. 12(S)-HETrEtreated mice showed no significant difference in tail-bleeding time compared with the control mice after excision of the distal segment (5 mm) of the tail ( Figure 4A ). To confirm this assay was accurately reporting bleeding risk, heparin-treated mice were also assayed for bleeding time and observed to have a severe bleeding diathesis (data not shown). A second hemostatic model was used to confirm hemostasis was not significantly altered after treatment with 12(S)-HETrE. This model involved arteriole puncture of the cremaster muscle induced by severe laser injury 27 to monitor the cessation time of red blood cell leakage from the punctured arteriole wall ( Figure 4B ; Movies VII and VIII in the online-only Data Supplement). No significant difference in the duration of red blood cell leakage was observed between 12(S)-HETrE and control-treated mice. In both the control and 12(S)-HETrE-treated mice, a stable, nonocclusive clot formed in response to laser puncture of the vessel wall, resulting in cessation of red blood cell leakage from the vessel. Both distinct hemostatic models suggested that 12(S)-HETrE did not disrupt hemostasis.
12(S)-HETrE Inhibits Platelets in a Gα s -Linked G-Protein-Coupled Receptor-Dependent Manner
COX-derived oxylipins that inhibit platelet function primarily exert their inhibition through the activation of a G-proteincoupled receptor (GPCR) coupled to Gα s resulting in adenylyl cyclase (AC) activation 28, 29 and the generation of cAMP. [30] [31] [32] [33] [34] To determine whether the DGLA-derived 12-LOX oxylipin 12(S)-HETrE could be regulating platelet reactivity in a similar manner, cAMP formation was measured in washed human platelets stimulated with 12(S)-HETrE or 12(S)-hydroperoxy-8Z,10E,14Z-eicosatrienoic acid (12(S)-HpETrE), a peroxidated, labile precursor of 12(S)-HETrE. After a 1-minute stimulation with 12(S)-HETrE or 12(S)-HpETrE, 16 human platelets exhibited a significant increase in the level of intracellular cAMP compared with vehicle-treated (DMSO) platelets ( Figure 5A ). As expected, platelets stimulated with forskolin, a direct activator of AC, also showed an increase in cAMP levels. 12(S)-HETrE-induced cAMP production was supportive of 12(S)-HETrE inhibiting platelets through the activation of AC. To assess whether 12(S)-HETrE inhibited platelet aggregation in an AC-dependent manner, platelets were pretreated with SQ 22536, an AC inhibitor 35 before incubation with 12(S)-HETrE or iloprost, a prostacyclin receptor agonist known to signal through AC. 36, 37 Iloprost and 12(S)-HETrE were unable to inhibit PAR4-AP-mediated platelet aggregation in platelets pretreated with SQ 22536 ( Figure 5B ), supporting an AC-dependent mechanism of platelet inhibition by 12(S)-HETrE.
The cAMP-activated kinase, PKA, phosphorylates multiple proteins in platelets including vasodilator-stimulated Figure 1F . Scale bar, 40 μm. Mean fluorescence intensity platelet and fibrin accumulation at the site of injury were recorded over time in (E) WT and (F) 12-LOX −/− mice. Data represent mean±SEM; 2-way ANOVA. NS indicates not significant; and RFI, relative fluorescence intensity. October 2016 phosphoprotein (VASP). Because serine 157 (S157) in VASP is a known PKA substrate, 38 VASP phosphorylation was used as a surrogate readout for PKA activation. Washed human platelets treated with DGLA or its 12-LOX metabolites (12(S)-HETrE or 12(S)-HpETrE) for 1 minute had enhanced VASP phosphorylation compared with DMSO-treated platelets ( Figure 5C ). As expected, forskolin-treated platelets also had an increase in VASP phosphorylation. These data demonstrate that the cAMP produced in platelets after exposure to 12(S)-HETrE is capable of eliciting physiological effects.
The activation of a GPCR coupled to Gα s leads to the dissociation of GDP and the subsequent binding of GTP to Gα s initiating a well-established signaling cascade resulting in increases in cAMP levels through the activation of AC. 39, 40 Because 12(S)-HETrE was shown to induce cAMP formation and inhibit platelet activation in an AC-dependent manner, we sought to determine whether 12(S)-HETrE could activate Figure 5D ). Activation of PAR4, a receptor that is known to selectively activate G q and G 12/13 , showed no [ 35 S]GTPγS binding confirming the selectivity for Gα s activation in the assay.
Discussion
Advances in antiplatelet therapy have significantly decreased the risk for morbidity and mortality because of thrombosis. However, even with the current standard-of-care antiplatelet therapies available, myocardial infarction and stroke caused by occlusive thrombotic events remain one of the primary causes of morbidity and mortality globally. Therefore, identification of novel therapies remains an unmet clinical need. One potential approach to reduce thrombus formation is the dietary intake of DGLA, a naturally occurring ω-6 PUFA, which has been shown to attenuate platelet aggregation ex vivo. [4] [5] [6] However, to date, the mechanism by which this inhibition is regulated and the ability of DGLA to inhibit thrombus formation in vivo have not been elucidated. Recently, our laboratory identified a 12-LOX-derived oxylipin of DGLA, 12(S)-HETrE, which inhibits human platelet activation. 16 In the current study, we sought to determine the relative contribution of 12-LOXderived metabolites in DGLA-mediated inhibition of platelet function and thrombosis in vivo. In contrast to the previously reported dependence of DGLA-mediated inhibition of platelet function on COX-derived metabolites, [4] [5] [6] 11 we show here that DGLA, but not 12(S)-HETrE, was unable to inhibit platelet aggregation in 12-LOX −/− mice suggesting that 12-LOX plays a key role in facilitating DGLA's antiplatelet effects.
In mice, 12-LOX was required for DGLA to impinge on platelet activation (Figures 1 and 2 ), suggesting that 12-LOX metabolites are responsible for the predominance of DGLA inhibitory effects in mice. Interestingly, human platelets stimulated with DGLA had higher VASP phosphorylation than those treated with 12(S)-HETrE ( Figure 5C ), indicating that other DGLA metabolites, such as COX-1-derived oxylipins ( Figure 3B ), may also contribute to VASP phosphorylation. This observation is supported by previous data that COX-1 or 12-LOX inhibitors partially suppresses the ability of DGLA to inhibit human platelet aggregation. 16 The proposed inhibitory effect mediated through 12-LOX seems paradoxical based on previous work in our laboratory and others showing that 12-LOX is a positive mediator of platelet function. 17, 21, 42, 43 However, because of the fact that 12-LOX is an enzyme whose function is to add an oxygen to a free fatty acid to produce a bioactive oxylipin, it is reasonable to conclude from the data presented here and elsewhere 5, 8 that the substrate for 12-LOX is the determining factor in its effect on platelets and ultimately thrombosis. This conclusion is supported by work in COX that shows that oxidation of AA results in a prothrombotic milieu of oxylipins, 44, 45 whereas other substrates such as DGLA can result in production of antithrombotic oxylipins. [4] [5] [6] 8, 46 The potent inhibition of thrombus formation by both DGLA and 12(S)-HETrE raises the potential that 12(S)-HETrE will cause excessive bleeding similar to other antiplatelet agents. [47] [48] [49] Two hemostatic assays, the tail-bleeding assay, and a second hemostatic model recently developed, the laser-induced cremaster arteriole puncture model, were used in this study to determine whether the DGLA metabolite 12(S)-HETrE prolonged bleeding after vascular injury. The mouse tail-bleeding assay for hemostasis is a physiological model, involving the measurement of cessation of bleeding after the excision of 5 mm of the distal tail, showed no prolonged bleed times in mice treated with 12(S)-HETrE compared with the control. However, prolonged bleeding was observed in tail-bleeding after heparin administration (data not shown), supporting the sensitivity of the tail-bleeding assay approach. A second hemostatic assessment, the laserinduced cremaster arteriole puncture model was performed by using the laser to puncture a hole through the cremaster arterial wall followed by measurement of the time required for fibrin and platelet plug formation in the mice. Similar to the tail-bleeding assay, no difference in bleeding times between control and 12(S)-HETrE-treated mice was observed, supporting the hypothesis that 12(S)-HETrE exerts an antithrombotic effect, while at the same time maintaining primary hemostasis. These data support 12(S)-HETrE either given directly or formed through ω-6 DGLA supplementation as a viable approach for prevention of thrombosis without creating a bleeding diathesis. 12(S)-HETrE was shown here to directly activate a yet to be determined Gα s -coupled GPCR. Direct addition of 12(S)-HETrE to purified platelet membranes was shown to increase the binding of [ 35 S]GTPγS, the hydrolysis-resistant GTP analog, to the Gα s -subunit resulting in cAMP formation, activation of PKA, and phosphorylation of VASP ( Figure 6 ). Further studies are required to identify whether 12(S)-HETrE is binding to a novel receptor or a previously characterized Gα s -coupled GPCR on the human and mouse platelet. Identification of this receptor will be essential to determine whether the mechanism of action elicited by 12(S)-HETrE is mediated through binding the GPCR in an allosteric or orthosteric manner and how this binding compares with other previously identified oxylipins shown to signal the platelet in a Gα s -dependent manner.
The discovery of 12(S)-HETrE regulation of platelet function at both the ex vivo and in vivo levels and the delineation of the mechanism of action through the Gα s -coupled GPCR establishes this oxylipin as an important eicosanoid in platelet biology. Beyond the platelet, it is also possible that 12(S)-HETrE plays an important role in the regulatory function of other vascular cells similar to what is observed with other key oxylipins produced in the platelet, such as prostacyclin, prostaglandin, PGD, and thromboxane. Furthermore, this study describes how an omega-6 essential PUFA, such as DGLA, can be used to alter the platelet signalosome to attenuate unwanted platelet activation and occlusive thrombus formation common in atherothrombotic diseases often leading to myocardial infarction and stroke. Additional studies will seek to understand more fully how this newly discovered regulatory pathway limits platelet function and thrombotic risk while minimizing the risk of bleeding. This study fully supports future efforts to target the 12(S)-HETrE pathway through the identification of the 12(S)-HETrE receptor as a first-in-class antiplatelet therapeutic with minimal risk of bleeding.
